Former U.S. President Donald Trump has announced that he plans to impose a 25% tariff on automobiles, semiconductors, and pharmaceutical products. After this announcement, pharma company stocks dropped sharply on Wednesday.
Some companies saw their shares fall by up to 10%. Earlier, Trump had announced a 25% tariff on steel and aluminum, which also affected stocks in that industry.
Big Loss for India
This decision is bad news for Indian pharma companies because the U.S. is India’s biggest importer of medicines.
đź“Š According to a Financial Express report, India exported $8.73 billion worth of medicines to the U.S. in 2024. This accounted for 31% of India’s total pharma exports. If Trump’s tariff plan is implemented, Indian pharma companies could face major losses.
Indian Pharma Industry Reacts
The Indian Pharmaceutical Alliance (IPA) has also expressed concern. Sudarshan Jain, IPA’s Secretary-General, said that India and the U.S. have had strong cooperation in healthcare for a long time. He hopes that both governments will negotiate to resolve this issue.
Pharma Stocks Take a Hit
Trump’s tariff proposal hit Indian stock markets hard.
📉 Major pharma stocks fell sharply:
- Dr. Reddy’s, Sun Pharma, and Cipla lost up to 10% in value.
- Nomura’s report predicts that Dr. Reddy’s, Lupin, and Cipla could see a 6.5% drop in earnings due to these tariffs.
Will the U.S. Also Suffer?
This tariff will not only harm India—it could hurt the U.S. as well.
🏥 The Healthcare Distribution Alliance (HDA) has warned that this move could lead to:
- Higher prices for generic medicines
- Shortages of essential drugs in the U.S.
If the U.S. imposes these tariffs, American consumers may have to pay more for medicines. The coming months will be crucial for the global pharma industry as both countries decide their next steps.
